The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
In the phase 2b STEP efficacy study evaluating the Merck recombinant Ad5 (rAd5) vector-based HIV-1 vaccine, vaccinees with baseline Ad5-specific neutralizing antibodies showed a 2.3-fold higher rate of HIV-1 acquisition as compared with controls 1, 2 . This potential increased HIV-1 susceptibility seemed to be durable for 452 weeks of follow-up and remains unexplained. These findings largely paralyzed the HIV-1 vaccine field and emphasized the importance of evaluating vector-specific immunity in the context of HIV-1 vaccine studies. A hypothesis has been proposed in which baseline Ad5-specific neutralizing antibodies may have been surrogate markers for Ad5-specific T lymphocyte responses, and anamnestic Ad5-specific CD4 + T lymphocytes after vaccination in Ad5-seropositive subjects may have served as increased numbers of targets susceptible to HIV-1 infection.
To explore the immunologic basis of this hypothesis, we analyzed adenovirus vector-specific immunity in 116 subjects vaccinated with 1 Â 10 10 or 1 Â 10 11 viral particles of the Merck rAd5 vector expressing HIV-1 Gag in the phase 1 studies that preceded the STEP study 3 . We used serum and peripheral blood mononuclear cells (PBMCs) at week 0 (baseline) and week 8 (4 weeks after the second vaccination) to assess vector-specific humoral and cellular immunity before and after vaccination.
We assessed baseline Ad5-specific neutralizing antibody titers by virus neutralization assays 4 and Ad5-specific T lymphocyte responses by interferon-g (IFN-g) enzyme-linked immunospot (ELISPOT) assays 5 
after Ad5 virus stimulation (Supplementary Methods).
We detected Ad5-specific cellular immune responses in 490% of subjects at baseline (Fig. 1a) , and these data were confirmed by ELISPOT assays using overlapping pooled peptides spanning the Ad5 hexon major capsid protein (data not shown). We speculate that the remarkably high frequency of Ad5-specific T lymphocyte responses reflects cross-reactive hexon-specific responses among multiple common subgroup C adenoviruses (data not shown). We observed no correlation between baseline Ad5-specific ELISPOT responses and neutralizing antibody titers ( Fig. 1a , P ¼ 0.83, Spearman rank-correlation test), demonstrating that Ad5-specific neutralizing antibodies are not simply surrogate markers for Ad5-specific T lymphocyte responses.
We next evaluated the evolution of Ad5-specific neutralizing antibodies after vaccination (Fig. 1b) . Individuals who were Ad5 seronegative at baseline developed high titers of Ad5-specific neutralizing antibodies at week 8. Subjects who were Ad5 seropositive at baseline developed supraphysiological titers of Ad5-specific neutralizing antibodies at week 8 that were significantly higher than those that developed in Ad5-seronegative subjects (P ¼ 5.4 Â 10 À4 , Wilcoxon rank-sum test, 1 Â 10 11 virus particle dose). In contrast, rAd5 vaccination did not elicit neutralizing antibodies to the rare Ad26, Ad35 or Ad48 serotypes [6] [7] [8] , indicating minimal cross-reactive neutralizing antibodies among these adenoviral serotypes (Supplementary Fig. 1 ).
Ad5-specific cellular immune responses at baseline were comparable between Ad5-seronegative and Ad5-seropositive subjects (Fig. 1c) . In Ad5-seronegative subjects, rAd5 vaccination resulted in a twofold (1 Â 10 10 virus particle dose, P ¼ 4.2 Â 10 À3 ) or a threefold (1 Â 10 11 virus particle dose, P ¼ 8.9 Â 10 À5 ) higher Ad5-specific ELISPOT responses at week 8 ( Fig. 1c) . In Ad5-seropositive subjects, vaccination resulted in only marginally higher Ad5-specific ELISPOT responses ( Fig. 1c ; 1 Â 10 10 virus particle dose, P ¼ 0.53; 1 Â 10 11 virus particle dose, P ¼ 0.043), which were significantly lower than those observed in Ad5-seronegative subjects (1 Â 10 10 virus particle dose, P ¼ 8.3 Â 10 À3 ; 1 Â 10 11 virus particle dose, P ¼ 2.3 Â 10 À3 ). These data suggest that baseline Ad5-specific neutralizing antibodies partially neutralized the rAd5 vaccine vector after vaccination and resulted in a lower effective dose of the vaccine in Ad5-seropositive subjects. Gag-specific antibody and T lymphocyte responses were similarly blunted by baseline Ad5-specific neutralizing antibodies, as expected 2,3,9 ( Supplementary  Fig. 2 ). Baseline Ad5-specific neutralizing antibodies did not affect the cytokine profile (IFN-g and interleukin-2 (IL-2) secretion greater than IL-4 and IL-10 secretion) or IgG subtype (IgG1 and IgG3 responses greater than IgG2 and IgG4 responses) of Gag-specific cellular or humoral immune responses after vaccination (data not shown).
We next evaluated the capacity of rAd5 vaccination to induce T lymphocyte responses to rare serotype adenoviruses. Ad26-, Ad35-and Ad48-specific ELISPOT responses were common (Fig. 1d-f ) despite the viruses' low seroprevalence 6, 7, 10 . Nevertheless, these responses were not detectably augmented after rAd5 vaccination (Fig. 1d-f ). These data indicate that cellular immune responses to the homologous Ad5 virus were substantially more potent than crossreactive responses to these rare Ad serotypes.
We confirmed these findings in CD4 + and CD8 + T lymphocyte subpopulations by multiparameter intracellular cytokine staining (ICS) assays 5, 11 ( Supplementary Fig. 3 and Supplementary Methods) in 23 subjects who received the 1 Â 10 11 virus particle dose of the vaccine. Vaccination resulted in clear increases in Ad5-specific IFN-g + CD4 + and IFN-g + CD8 + T lymphocyte responses in Ad5-seronegative subjects, but we observed less convincing responses in Ad5-seropositive individuals (Fig. 2a) . Similar results were evident for Ad5-specific IL-2 + T lymphocyte responses (data not shown). In contrast, we did not observe any clear changes in Ad26-specific CD4 + and CD8 + T lymphocytes after rAd5 vaccination (Fig. 2a) . We also found no perturbation of total, CCR5 + , CD45RO + CD27 + central memory or CD45RO + CD27 -effector memory CD4 + T lymphocyte subpopulations (Fig. 2b) and no sustained Ki67 + activation of any of these CD4 + T lymphocyte subpopulations (Fig. 2c,d ) at week 8. We also did not detect any differences in Ki67 expression on Ad5-specific CD4 + T lymphocytes between Ad5-seronegative and Ad5-seropositive subjects ( Supplementary Fig. 4a ). Short-term cellular immune activation for 1-2 weeks after rAd5 vaccination has been reported 2 , but these transient effects probably do not explain the durable increase in HIV-1 susceptibility for 452 weeks in the STEP study 1 .
In summary, Ad5-specific neutralizing antibodies at baseline are not surrogate markers for Ad5-specific cellular immune responses, and Ad5-specific T lymphocyte responses after rAd5 vaccination were lower in baseline Ad5-seropositive subjects as compared with baseline Ad5-seronegative subjects. We also observed no evidence of sustained modulation or activation of CD4 + T lymphocyte subpopulations after rAd5 vaccination. These data challenge the hypothesis that anamnestic Ad5-specific CD4 + T lymphocyte responses after rAd5 vaccination were responsible for the potential enhancement of HIV-1 acquisition in Ad5-seropositive subjects in the STEP study. A caveat is that we were unable to assess mucosal immune responses in the present study, although we did not detect differences between Ad5-seronegative and Ad5-seropositive subjects in a 4 and b 7 integrin expression on total or Ad5-specific peripheral CD4 + T lymphocytes (Supplementary Fig. 4b ). An alternative model has been suggested in which the potential enhancement of HIV-1 susceptibility in Ad5-seropositive subjects may have been due to immune complex formation after rAd5 vaccination 12 . If this model proves correct, then the use of vaccine vectors that evade baseline vector-specific neutralizing antibodies may prove useful. Subjects gave informed consent, and studies were approved by the Institutional Review Board of Beth Israel Deaconess Medical Center. All coauthors discussed the data and contributed to writing the manuscript.
